

13.2351% (4.4117% p.a.) ZKB Reverse Convertible on worst of Vifor Pharma AG rs/Lonza Group AG rs/Zurich Insurance Group AG rs/Helvetia Holdina AG rs

13.12.2021 - 13.12.2024 | Swiss Security Code 113 974 534

Summary

This Summary is to be understood as an introduction to the present Final Terms. Any investment decision in relation to the structured products must be based on the information contained in the base prospectus and in these Final Terms in their entirety and not on the Summary. In particular, each investor should consider the risk factors contained in these Final Terms and in the base prospectus.

The Issuer can only be held liable for the content of this Summary if the Summary is misleading, incorrect or contradictory when read together with the other parts of the Final Terms and the base prospectus.

Information on the securities
<p>Type of product: ZKB Reverse Convertible on worst of SSPA Category: Reverse Convertible (1220, according to the Swiss Derivative Map) ISIN: CH1139745348 Issuer: Zürcher Kantonalbank Underlyings:</p> <ul style="list-style-type: none"> - Vifor Pharma AG registered share - Lonza Group AG registered share - Zurich Insurance Group AG registered share - Helvetia Holding AG registered share <p>Initial Fixing Date: December 6, 2021 Payment Date: December 13, 2021 Final Fixing Date: December 6, 2024 Redemption Date: December 13, 2024 Settlement type: cash or physical Coupon: 13.2351% (4.4117% p.a.) Cap Level: 70.00% of Initial Fixing Value</p>
Information on the offer and admission to trading
<p>Place of the offer: Switzerland Issue amount/Denomination/Trading Units: Up to CHF 40'000, without the possibility to increase/CHF 10'000 per product/CHF 10'000 or multiples thereof Issue Price: 100% of the Denomination (CHF 10'000) Information on listing: The product shall not be listed on an exchange.</p>

Final Terms

1. Product specific conditions and product description

Product Category/Name

Yield Enhancement/Reverse Convertible (1220, according to the Swiss Derivative Map provided by the Swiss Structured Products Association)

Regulatory Notification

This product does not constitute a collective investment scheme within the meaning of the Swiss Federal Act on Collective Investment Schemes (CISA) and is not subject to authorisation or supervision by the Swiss Financial Market Supervisory Authority FINMA. The Issuer risk is borne by investors.

Issuer

Zürcher Kantonalbank, Zürich

Rating of the Issuer

Standard & Poor's AAA, Moody's Aaa, Fitch AAA

**Lead Manager, Paying Agent,
Exercise and Calculation Agent**

Zürcher Kantonalbank, Zürich

Swiss Security Code/ISIN

113 974 534 (not listed) / CH1139745348

**Issue amount/
Denomination/
Trading Units**

Up to CHF 40'000, without the possibility to increase/
CHF 10'000 per product/
CHF 10'000 or multiples thereof

Issue Price

100% of the Denomination

Currency

CHF

Underlyings

Underlying	Type of Underlying/ Domicile	ISIN/ Bloomberg	Trading place/ Price source
Vifor Pharma AG	Registered share/ Switzerland	CH0364749348/ VIFN SE EQUITY	SIX Swiss Exchange
Lonza Group AG	Registered share/ Switzerland	CH0013841017/ LONN SE EQUITY	SIX Swiss Exchange
Zurich Insurance Group AG	Registered share/ Switzerland	CH0011075394/ ZURN SE EQUITY	SIX Swiss Exchange
Helvetia Holding AG	Registered share/ Switzerland	CH0466642201/ HELN SE EQUITY	SIX Swiss Exchange

**Initial Fixing Value (100.00%)
Cap Level (70.00%)
Ratio**

Underlying	Initial Fixing Value	Cap Level	Ratio
Vifor Pharma AG	CHF 119.00	CHF 83.30	120.048019
Lonza Group AG	CHF 709.00	CHF 496.30	20.149103
Zurich Insurance Group AG	CHF 393.00	CHF 275.10	36.350418
Helvetia Holding AG	CHF 105.30	CHF 73.71	135.666802

**Initial Fixing Date/
Initial Fixing Value**

Vifor Pharma AG rs: Theoretically calculated price on December 6, 2021 at 16:52h CET
Lonza Group AG rs: Theoretically calculated price on December 6, 2021 at 16:52h CET
Zurich Insurance Group AG rs: Theoretically calculated price on December 6, 2021 at 16:52h CET
Helvetia Holding AG rs: Theoretically calculated price on December 6, 2021 at 16:52h CET

Payment Date

December 13, 2021

Last Trading Date

December 6, 2024

**Final Fixing Date/
Final Fixing Value**

Vifor Pharma AG rs: Closing price on SIX Swiss Exchange on December 6, 2024
Lonza Group AG rs: Closing price on SIX Swiss Exchange on December 6, 2024
Zurich Insurance Group AG rs: Closing price on SIX Swiss Exchange on December 6, 2024
Helvetia Holding AG rs: Closing price on SIX Swiss Exchange on December 6, 2024

**Redemption Date/
Date of delivery**

December 13, 2024

Coupon

13.2351% (4.4117% p.a.) per Denomination CHF 10'000
interest part 0.0000% p.a. (CHF 0.00), premium part 4.4117% p.a. (CHF 441.17)

**Coupon Dates/
Coupon**

	Coupon Date*	Coupon
t = 1	14.03.2022	1.1029% (CHF 110.29)
t = 2	13.06.2022	1.1029% (CHF 110.29)
t = 3	13.09.2022	1.1029% (CHF 110.29)
t = 4	13.12.2022	1.1029% (CHF 110.29)
t = 5	13.03.2023	1.1029% (CHF 110.29)
t = 6	13.06.2023	1.1029% (CHF 110.29)
t = 7	13.09.2023	1.1029% (CHF 110.29)
t = 8	13.12.2023	1.1029% (CHF 110.29)
t = 9	13.03.2024	1.1029% (CHF 110.29)
t = 10	13.06.2024	1.1029% (CHF 110.29)
t = 11	13.09.2024	1.1029% (CHF 110.29)
t = 12	13.12.2024	1.1029% (CHF 110.29)

* modified following business day convention

Coupon Calculation Method	30/360 (German), modified following
Redemption method	If the Final Fixing Value of all Underlyings is at or above the Cap Level, the Redemption amounts to 100% of Denomination. If the Final Fixing Value of one or more Underlyings is below the Cap Level, the investor receives a physical delivery of the worst performing Underlying (between Initial Fixing Date and Final Fixing Date). The number of Underlyings per Denomination is defined in Ratio (fractions will be paid in cash, no cumulation). The Coupons are paid out on the respective Coupon Date independent of the performance of the Underlyings.
Listing/Secondary market	The product shall not be listed on an exchange. The Issuer commits to quote bid prices.
Quotation Type	During the lifetime, this product is traded flat accrued interest, i.e. accrued interest is included in the trading price ('dirty price').
Clearing Agent	SIX SIS AG
Distribution Fees	Distribution fees in the form of a discount on the Issue price, reimbursement of a part of the Issue price or other one-off and/or periodic charges may have been paid to one or several distribution partners of this product. The Distribution Fees paid out to distribution partners may amount up to 0.13% p.a.
Sales: 044 293 66 65	SIX Telekurs: .zkb Internet: www.zkb.ch/finanzinformationen
	Reuters: ZKBSTRUCT Bloomberg: ZKBY <go>
Key elements of the product	This product is a combined investment instrument that consists of a fixed income security and the sale of a "out-of-the-money" put option. This allows the investor to benefit from the current volatility of the Underlyings. The product pays out attractive Coupons during the term. An above-average return is achieved when prices fall slightly, stagnate or rise slightly. If the Final Fixing Value of all Underlyings is at or above the Cap Level, the investor receives a cash redemption in the amount of the Denomination. If the Final Fixing Value of at least one Underlying is below the Cap Level, the investor will receive a physical delivery of a number of Underlyings as defined under "Redemption method" of the Underlying with the worst performance between Initial Fixing Date and Final Fixing Date.
Taxes	The product is considered as transparent and has no predominant one-off interest (Non-IUP). The Coupon of 4.4117% p.a. is divided into a premium payment of 4.4117% p.a. and an interest payment of 0.00% p.a.. The option premium part qualifies as capital gain and is not subject to Swiss income tax for private investors with Swiss tax domicile. The interest payment is subject to income tax at the time of payment. The Swiss withholding tax is levied. In the case of physical delivery of the Underlying at maturity, the federal securities transfer stamp is levied on the basis of the Cap level. The Federal securities transfer stamp tax is levied on secondary market transactions. The product may be subject to further withholding taxes or duties, in particular under the rules of FATCA or Sect. 871(m) U.S. Tax Code or foreign financial transaction taxes. All payments from this product are made after deduction of any withholding taxes and levies. The information above is a summary only of the Issuer's understanding of current law and practice in Switzerland relating to the taxation of these products. The relevant tax law and practice may change. The Issuer does not assume any liability in connection with the above information. The tax information only provides a general overview and can not substitute the personal tax advice to the investor.
Documentation	This document is a non-binding English translation of the Final Terms (Endgültige Bedingungen) published in German and constituting the Final Terms in accordance with article 45 of the Federal Act on Financial Services (FinSA) and a simplified prospectus pursuant to article 5 para. 2 CISA in the version dated 1 March 2013. The English language translation is provided for convenience only. The binding German version of these Final Terms together with the applicable Base prospectus of the Issuer for the issuance of structured products approved by SIX Exchange Regulation Ltd (together with any supplements thereto, the "Base prospectus") constitute the product documentation for the present issue. If this structured product was offered for the first time prior to the date of the respective applicable Base prospectus, the further legally binding product terms and conditions (the "Relevant Conditions") are derived from the Base prospectus or issuance program which was in force at the time of the first offer. The information on the Relevant Conditions is incorporated by

reference of the respective Base prospectus or issuance program into the applicable Base prospectus in force at the time of issuance. Except as otherwise defined in these Final Terms, the terms used in these Final Terms have the meaning given to them in the Base prospectus or the Relevant Conditions. In case of discrepancies between information or the provisions in these Final Terms and those in the Base prospectus or the Relevant Conditions, the information and provisions in these Final Terms shall prevail. Structured products will be issued in the form of uncertificated securities (Wertrechte) and registered as book-entry securities (Bucheffekten) with SIX SIS AG. Investors have no right to require the issuance of any certificates or any proof of evidence for the products. **These Final Terms and the Base prospectus can be ordered free of charge at Zürcher Kantonalbank, Bahnhofstrasse 9, 8001 Zurich, dept. VRIE or by e-mail at documentation@zkb.ch. They are also available on <https://www.zkb.ch/finanzinformationen>.**

Information on the Underlying

Information on the performance of the Underlyings is publicly available on www.bloomberg.com. The transfer of the Underlyings is conducted in accordance with their statutes.

Notifications

Any notice by the Issuer in connection with this product, in particular any notice in connection with modifications of the terms and conditions will be validly published on the website <https://www.zkb.ch/finanzinformationen> to the corresponding product. The Swiss security code search button will lead you directly to the relevant product.

Governing Law/Jurisdiction

Swiss Law/Zurich

2. Profit and Loss Expectations

Profit and Loss Expectations at Maturity

Price	Worst Underlying Percent	Redemption		
		Product	Coupon	Performance in %
CHF 83.30	-30.00%	CHF 10'000.00	CHF 1'323.48	13.2348%
CHF 95.20	-20.00%	CHF 10'000.00	CHF 1'323.48	13.2348%
CHF 107.10	-10.00%	CHF 10'000.00	CHF 1'323.48	13.2348%
CHF 119.00	0.00%	CHF 10'000.00	CHF 1'323.48	13.2348%
CHF 130.90	10.00%	CHF 10'000.00	CHF 1'323.48	13.2348%
CHF 142.80	20.00%	CHF 10'000.00	CHF 1'323.48	13.2348%
CHF 154.70	30.00%	CHF 10'000.00	CHF 1'323.48	13.2348%

If the Final Fixing Value of all Underlyings is at or above the Cap Level, the performance of the product is always given by the Coupons paid out during the term (acc. "Coupon Dates"), in this case 13.2348%. However, if the Final Fixing Value of at least one Underlying is below the Cap Level, the investor will receive a physical delivery of a number of Underlyings as defined in Ratio. Therefore, the investor may suffer a partial or total loss. The acquisition price of the delivered Underlyings is 70.00% of the Initial Fixing Value, which means that the performance of the product is less negative than the performance of the Underlying. This negative performance is reduced by the guaranteed Coupons paid out during the term.

The table above is valid at maturity only and is by no means meant as a price indication for the present product throughout its lifetime. Additional risk factors may have a significant impact on the value of the product during the term. The price quoted on the secondary market can therefore deviate substantially from the above table. For this table it was assumed, that Vifor Pharma AG rs was the worst performing Underlying. This selection is just a representative example of the possible alternatives. Currency risks between the Underlying and the product are not considered in the table.

3. Material Risks for Investors

Issuer Risk

Obligations under these structured products constitute direct, unconditional and unsecured obligations of the Issuer and rank pari passu with other direct, unconditional and unsecured obligations of the Issuer. The value of the structured product not only depends on the performance of the Underlying and other developments in the financial markets, but also on the solvency of the Issuer, which may change during the term of this structured product.

Specific product risks

Structured products are complex financial instruments, which entail considerable risks and, accordingly, are only suitable for investors who have the requisite knowledge and experience and understand thoroughly the risks connected with an investment in these structured products and are capable of bearing the economic risks. The loss potential of an investment in ZKB Reverse Convertibles on worst of in the case of a title delivery is limited to the

difference between the purchase price of the product and the cumulative value of the number of Underlyings as defined in 'Redemption Method'. The Coupon, which is paid out in any case, reduces the loss of the product compared to a direct investment in the worst performing Underlying. The price of the Underlyings may be significantly below the Cap Level at redemption.

The product is denominated in CHF. If the investor's reference currency differs from the CHF, the investor bears the risk between the CHF and his reference currency.

4. Additional Terms

Modifications

If an extraordinary event as described in the base prospectus occurs in relation to an Underlying or if any other extraordinary event occurs, which makes it impossible or particularly cumbersome for the Issuer, to fulfill its obligations under the products or to calculate the value of the products, the Issuer shall at its own discretion take all the necessary actions and, if necessary may modify the terms and conditions of these products at its own discretion in such way, that the economic value of the products after occurrence of the extraordinary event corresponds, to the extent possible, to the economic value of the products prior to the occurrence of the extraordinary event. Specific modification rules for certain types of Underlyings stated in the base prospectus shall prevail. If the Issuer determines, for whatever reason, that an adequate modification is not possible, the Issuer has the right to redeem the products early.

Market Disruptions

Compare specific provisions in the base prospectus.

Prudential Supervision

As a bank within the meaning of the Swiss Federal Act on Banks and Savings Banks (BankG; SR 952.0) and a securities firm within the meaning of the Swiss Federal Act on Financial Institutions (FinIAG; SR 954.1), Zürcher Kantonalbank is subject to the prudential supervision of FINMA, Laupenstrasse 27, CH-3003 Bern, <https://www.finma.ch>.

Recording of Telephone Conversations

Investors are reminded, that telephone conversations with trading or sales units of the Zürcher Kantonalbank are recorded. Investors, who have telephone conversations with these units consent tacitly to the recording.

Further Information

This document constitutes neither an offer nor a recommendation or invitation to purchase financial instruments and can't replace the individual investor's own judgement. The information contained in this document does not constitute investment advice but is intended solely as a product description. An investment decision should in any case be made on the basis of these Final Terms and the base prospectus. Particularly, before entering into a transaction, the investor should, if necessary with the assistance of an advisor, examine the conditions for investment in the product in consideration of his personal situation with regard to legal, regulatory, tax and other consequences. Only an investor who is aware of the risks of the transaction and has the financial capacity to bear any losses should enter into such transactions.

Material Changes

Since the end of the last financial year or the date of the interim financial statements, there have been no material changes in the assets, financial or revenue position of the Issuer.

Responsibility for the Final Terms

Die Zürcher Kantonalbank, Zürich, assumes responsibility for the content of these Final Terms and hereby declares that, to its knowledge, the information contained in these Final Terms is correct and no material circumstances have been omitted.

Zurich, December 6, 2021